ALXN News and Press, Alexion Pharmaceuticals Inc. From 07/31/20

Image source: The Motley Fool. Alexion Pharmaceuticals   (NASDAQ: ALXN) Q2 2020 Earnings Call Jul 30, 2020 , 8:00 a.m. ET Operator Continue reading

Though volatility never officially goes away, this has been a year unlike any other for Wall Street and investors. We've witnessed a good decade's worth of volatility crammed into the past five months as the CBOE Volatility Index hit a record high and remains at levels that are well above its ...

Alexion Pharmaceuticals, Inc. (ALXN) Q2 2020 Results Conference Call July 30, 2020 08:00 AM ET Company Participants Christopher Stevo - Head of Investor Relations Ludwig Hantson - Chief Executive Officer Aradhana Sarin - Chief Financial Officer John Orloff - Global Head of R&am...

Alexion Pharmaceuticals   (NASDAQ: ALXN) stock has been on a big roll over the last few months. However, it hasn't been enough to outperform the S&P 500 index -- and Alexion's shares are still in negative territory year to date. But Alexion provided good news to investors with its ...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Alexion Pharmaceuticals ( ALXN ) Q2 results : More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) : Q2 Non-GAAP EPS of $3.11 beats by $0.53 ; GAAP EPS of -$4.84 misses by $6.97 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

2Q20 total revenues of $1,444.6 million, a 20% increase over 2Q19 2Q20 GAAP diluted EPS of $(4.84); non-GAAP diluted EPS of $3.11 Achieved goal of establishing ULTOMIRIS ® (ravulizumab-cwvz) as new standard of care in PNH with more than 70% patient conversion from SOLIR...

Alexion Pharmaceuticals (NASDAQ: ALXN ) is scheduled to announce Q2 earnings results on Thursday, July 30th, before market open. The consensus EPS Estimate is $2.58 (-2.3% Y/Y) and the consensus Revenue Estimate is $1.27B (+5.8% Y/Y). Over the last 2 years, ALXN has beaten EPS estimat...

Many investors have made tons of money by investing in small-cap biotech stocks, especially those that are still relatively obscure. One potential investment candidate that's slipped under the radar due to the coronavirus pandemic is Omeros Corporation (NASDAQ: OMER) . A biotech company that ...